RxSight (RXST) Research & Development (2020 - 2026)

RxSight (RXST) has reported Research & Development for 7 consecutive years, with $9.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 9.59% year-over-year to $9.2 million; the trailing twelve-month figure through Jun 2026 stood at $36.7 million (down 5.06% YoY), and the FY2025 full-year result was $38.5 million, up 12.17% from the prior year.
• Research & Development retreated to $9.2 million in Q2 2026 per RXST's latest filing, from $9.5 million in the prior quarter.
• Across five years, Research & Development topped out at $10.4 million in Q1 2025 and bottomed at $6.2 million in Q2 2022.
• Historically, Research & Development has averaged $8.1 million across 5 years, with a median of $8.2 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Research & Development increased 29.09% in 2025, then declined 9.59% in 2026.
• Over 5 years, Research & Development stood at $6.7 million in 2022, then rose by 9.88% to $7.3 million in 2023, then climbed by 25.42% to $9.2 million in 2024, then fell by 3.28% to $8.9 million in 2025, then gained by 3.73% to $9.2 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $9.2 million, $9.5 million, and $8.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.